Magnesium-zinc-calcium-vitamin D co-supplementation improves glycemic control and markers of cardio-metabolic risk in gestational diabetes: a randomized, double-blind, placebo-controlled trial.
Appl Physiol Nutr Metab. 2018 Jan 9. Epub 2018 Jan 9. PMID: 29316405
To the best our knowledge, data on the effects of magnesium-zinc-calcium-vitamin D co-supplementation on glycemic control and markers of cardio-metabolic risk in gestational diabetes mellitus (GDM) are scarce. The purpose of this study was to establish the effects of magnesium-zinc-calcium-vitamin D co-supplementation on glycemic control and markers of cardio-metabolic risk of GDM patients. Sixty patients with GDM, aged 18-40 years old were randomised into two groups to intake either magnesium-zinc-calcium-vitamin D co-supplements or placebo (n=30 each group) for 6 weeks in a randomized, double-blind, placebo-controlled trial. Fasting blood samples were taken at baseline and week 6 to quantify related markers. After the 6-week intervention, compared with the placebo, magnesium-zinc-calcium-vitamin D co-supplementation supplementation resulted in significant reductions in fasting plasma glucose (-0.37±0.09 vs. +0.01±0.09 mmol/L, P=0.003), serum insulin levels (-21.0±4.8 vs. +7.2±4.8 pmol/L, P<0.001), homeostatic model of assessment for insulin resistance (-1.0±1.1 vs. +0.3±1.3, P<0.001), and a significant increase in quantitative insulin sensitivity check index (+0.02±0.03 vs. -0.002±0.03, P=0.003). In addition, magnesium-zinc-calcium-vitamin D co-supplementation significantly decreased serum triglycerides (-0.25±0.10 vs. +0.34±0.10 mmol/L, P=0.001) and VLDL-cholesterol concentrations (-0.11±0.04 vs. +0.15±0.04 mmol/L, P=0.001) compared with the placebo. Overall, the results of this study demonstrated that magnesium-zinc-calcium-vitamin D co-supplementation for 6 weeks among patients with GDM had beneficial effects on glycemic control and few markers of cardio-metabolic risk.